GSK's (GSK) Bexsero received a recommendation from the European Medicines Agency to immunize newborns against meningococcal disease, the regulator said Friday.
The EMA's Committee for Medicinal Products for Human Use recommended the vaccine for meningococcal disease caused by Neisseria meningitidis group B in children from 6 weeks of age and older, compared with two months and older previously, the regulator said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments